Lindbrook Capital, LLC Athira Pharma, Inc. Transaction History

Lindbrook Capital, LLC

$1.06 Billion
Q1 2025

A detailed history of Lindbrook Capital, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 8,920 shares of ATHA stock, worth $41,121. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,920

Previous 8,920 -0.0%

Holding current value

$41,121

Previous $5,000 60.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$0.42 - $3.43 $1,603 - $13,095	-3,818 Reduced 29.97%	8,920 $4,000
Q1 2024 Apr 25, 2024	BUY	$2.24 - $4.15 $6,720 - $12,450	3,000 Added 30.81%	12,738 $34,000
Q3 2023 Oct 25, 2023	SELL	$1.9 - $3.16 $3,171 - $5,274	-1,669 Reduced 14.63%	9,738 $19,000
Q4 2022 Jan 24, 2023	SELL	$2.76 - $3.71 $15,215 - $20,453	-5,513 Reduced 32.58%	11,407 $0
Q3 2022 Nov 10, 2022	SELL	$2.93 - $3.96 $19,045 - $25,740	-6,500 Reduced 27.75%	16,920 $50,000
Q2 2022 Aug 01, 2022	SELL	$2.74 - $13.43 $2,063 - $10,112	-753 Reduced 3.12%	23,420 $71,000
Q1 2022 Apr 21, 2022	BUY	$8.96 - $13.51 $8,538 - $12,875	953 Added 4.1%	24,173 $326,000
Q4 2021 Jan 18, 2022	BUY	$9.17 - $16.39 $75,093 - $134,217	8,189 Added 54.48%	23,220 $303,000
Q3 2021 Nov 05, 2021	SELL	$9.15 - $11.09 $229,738 - $278,447	-25,108 Reduced 62.55%	15,031 $141,000
Q2 2021 Jul 27, 2021	BUY	$10.24 - $20.87 $155,770 - $317,474	15,212 Added 61.03%	40,139 $411,000
Q1 2021 Apr 28, 2021	SELL	$16.9 - $29.77 $35,490 - $62,517	-2,100 Reduced 7.77%	24,927 $459,000
Q4 2020 Jan 27, 2021	BUY	$16.48 - $34.3 $188,728 - $392,803	11,452 Added 73.53%	27,027 $926,000
Q3 2020 Nov 03, 2020	BUY	$16.02 - $18.46 $249,511 - $287,514	15,575 New	15,575 $288,000

Others Institutions Holding ATHA

# of Institutions

Shares Held

1.34M

Call Options Held

Put Options Held

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $174M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account

Lindbrook Capital, LLC Athira Pharma, Inc. Transaction History